Evaxion Presents Promising Data on Cancer Vaccine EVX-01
Evaxion A/S (NASDAQ: EVAX), a pioneering TechBio firm renowned for its innovative AI-Immunology™ powered vaccines, is set to unveil an array of results from its phase 2 trial that explores the effectiveness of its personalized cancer vaccine, EVX-01. This significant presentation will occur during the prestigious European Society for Medical Oncology (ESMO) Congress this year in Berlin, highlighting a two-year synopsis of clinical efficacy, immunogenicity, and safety data.
Key Findings from the Phase 2 Trial
The presentation will feature a comprehensive set of clinical data, focusing on vital metrics such as the best overall response, rates for deepened response and conversion, as well as the durability of response to this innovative therapy. The study emphasizes the T-cell response induced by the vaccine, offering insights into its safety profile and effectiveness.
Anticipation for Data Presentation
Birgitte Rønø, the Chief Scientific Officer and interim CEO of Evaxion, expressed enthusiasm about the upcoming presentation, noting the importance of the occasion. She stressed the opportunity to engage with medical and scientific professionals as well as potential partners, underscoring the significant interest surrounding EVX-01 and the broader landscape of personalized cancer vaccines.
Evaxion's Presence at the Conference
Evaxion will have a dedicated booth throughout the congress, providing a platform for dialogue and discussions regarding the trial data with interested stakeholders. This direct engagement with attendees allows for deeper insights and shared perspectives on the future of cancer treatment.
Understanding EVX-01
Tailored using Evaxion's proprietary AI-Immunology™ platform, EVX-01 is specifically designed for the treatment of advanced melanoma. The findings from previous trials have been compelling, with interim one-year results showcased at the previous ESMO Congress. These results revealed a remarkable 69% overall response rate and a significant reduction in tumor target lesions in 15 out of 16 patients.
Correlation Between AI Predictions and Immune Responses
Further analysis determined a strong link between the AI-Immunology™ platform predictions and the immune responses produced by the unique neoantigens in the EVX-01 vaccine, showcasing a significant p-value of 0.00013. Notably, recent immune data indicates that a majority—80%—of the targets elicited a tumor-specific immune response, reinforcing the efficacy of this therapeutic approach.
Combination Therapy with Keytruda
The phase 2 trial evaluates the administration of EVX-01 alongside MSD’s KEYTRUDA® (pembrolizumab), a widely recognized anti-PD-1 therapy, in patients diagnosed with advanced melanoma. Every participant in the study receives a uniquely formulated vaccine designed based on their individual biological makeup, highlighting the personalized nature of this treatment.
Details of the Upcoming Presentation
The oral presentation will cover crucial findings outlined in the abstract, titled: "EVX-01, a personalized cancer vaccine, induces potent T-cell responses and durable disease control in advanced melanoma: 2-year follow-up." Evaxion's session is scheduled for October 17 at 14:10 CEST, where Dr. Muhammad Adnan Khattak, a key trial investigator, will lead the discussion.
Engaging Webinar Post-Presentation
On October 22, Evaxion will host an online webinar where Dr. Khattak will delve deeper into the two-year data and address the challenges faced in treating advanced melanoma. Participants can register to attend this session and are encouraged to engage during the Q&A portion.
About EVX-01 and Personalized Treatment
EVX-01 serves as Evaxion's lead clinical asset, representing a significant stride forward in personalized cancer treatment. This innovative vaccine aims to harness the patient’s immune system, effectively targeting their specific tumor profile and immune characteristics. The results of previous trials reflect the promising potential for significant therapeutic responses.
Contact Information for Further Inquiries
For additional information regarding Evaxion and its pioneering efforts in AI-driven immunotherapies, interested parties can contact:
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai
Frequently Asked Questions
What is the significance of Evaxion's phase 2 trial data presentation?
The trial data is crucial as it delivers insights into the effectiveness, safety, and immune responses associated with the EVX-01 cancer vaccine, contributing to advancements in personalized cancer treatment.
When will the ESMO Congress take place?
The ESMO Congress will take place from October 17 to 21, with Evaxion’s key presentation scheduled for October 17.
Who is Dr. Muhammad Adnan Khattak?
Dr. Khattak is the Director of Oncology at One Clinical Research and will be presenting at the ESMO Congress as a key opinion leader in assessing the trial’s findings.
What is the correlation mentioned in the trial results?
The trial results indicate a significant correlation between the AI platform predictions and the immune responses elicited by the vaccine, highlighting the predictive capability of the AI-Immunology™ platform.
What role does KEYTRUDA® play in the trial?
KEYTRUDA® is being used in conjunction with EVX-01 in the trial to assess combined efficacy against advanced melanoma, leveraging the benefits of both therapies.
